Sign in

You're signed outSign in or to get full access.

Matthew Hornishorn

Research Analyst at Oppenheimer

Matthew Hershenhorn is an Equity Research Associate and Analyst at Oppenheimer & Co. Inc., specializing in high-growth biotechnology companies. He actively covers firms such as Axsome Therapeutics and CBEYOND Therapeutics, engaging on key clinical trial metrics including weight loss efficacy, secondary endpoints, discontinuation rates, and extension study eligibility. Hershenhorn is a FINRA-registered representative, demonstrating professional credentials in equity research, though specific performance metrics like success rates or rankings on platforms such as TipRanks are not publicly detailed in available sources.

Matthew Hornishorn's questions to Axsome Therapeutics (AXSM) leadership

Question · Q4 2025

Matthew Hornishorn inquired about the likely label language for Auvelity in Alzheimer's disease agitation (ADA) regarding its safety data and differentiation versus Rexulti, particularly concerning advantages in elderly patients.

Answer

Mark Jacobson, Chief Operating Officer, stated it's too early to comment on potential label language but expects the safety profile in the ADA patient population to be described. Ari Maizel, Chief Commercial Officer, highlighted Auvelity's rapid onset, durability, low side effects, non-antipsychotic nature, and monotherapy MDD approval as key differentiators, especially given the comorbidity with Alzheimer's agitation.

Ask follow-up questions

Fintool

Fintool can predict Axsome Therapeutics logo AXSM's earnings beat/miss a week before the call

News for Covered Companies

Axsome Surges 20% to All-Time High on FDA Priority Review for Alzheimer's Drug

Axsome Surges 20% to All-Time High on FDA Priority Review for Alzheimer's Drug

AXSMDec 31, 2025